• Publications
  • Influence
Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients.
S-1 improves the tumour-selective toxicity of 5-FU by the actions of two modulators, CDHP and Oxo, and was effective and well tolerated in patients with advanced gastric cancer. Expand
[Phase I study].
  • T. Taguchi
  • Medicine
  • Gan to kagaku ryoho. Cancer & chemotherapy
  • 1 April 1995
Criticisms and proposals were presented from the standpoint of implementation with regard to the objectives, person in charge, test facilities, patients tested and test design in the first phaseExpand
Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.
S-1 may improve patients' quality of life because the pharmacokinetics of orally administered S-1 is almost similar to that of continuous i.v. infusion of 5-FU, it is concluded. Expand
Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer.
This schedule appears to allow a CPT-11 dose intensity which is double the dose intensity possible on a once-a-month schedule, however, careful supervision to assess gastrointestinal toxic effects and myelosuppression is indispensable because of wide individual differences in drug tolerance. Expand
An Early Phase II Study of Oral S-1, a Newly Developed 5-Fluorouracil Derivative for Advanced and Recurrent Gastrointestinal Cancers
The antineoplastic effect of S-1, an antitumor agent developed, based on the biochemical modulation of FT by 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo), in a molar ratio of 1:0.4:1 is considered to have positive effects in patients with advanced gastrointestinal cancer. Expand
Comparison of FDG-PET with MIBI-SPECT in the detection of breast cancer and axillary lymph node metastasis.
Neither FDG-PET nor MIBI-SPECT is sufficiently sensitive to rule out axillary lymph node metastasis in the detection of breast cancer and axillaryymph node metastase in the same patients, indicating that MIBI's SPECT is comparable with FDg-PET in detecting breast cancer. Expand
Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors
The maximum tolerated dose (MTD) of YM155 was determined to be 8.0 mg/m2/d, and the safety profile, plasma concentrations achieved, and antitumor activity observed merit further studies with this survivin suppressant, alone and in combination regimens. Expand
Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.
CPT-11 showed promising antitumor activity against metastatic colorectal cancer that was resistant to prior therapy and could be continued on an outpatient basis for patients without severe toxicity. Expand
[Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group].
CPT-11 showed activity against advanced gastric cancer, suggesting that further clinical studies of CPT-11 combined with other active chemotherapy agents are warranted. Expand
Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma
It is suggested that S-1 achieves similar responses to those of infusional 5-FU plus leucovorin and shows the potential of another biochemical modulation with easily manageable toxicity. Expand